NEW YORK, April 9, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Biogen Idec Inc. (NASDAQ: BIIB), Actavis Plc (NYSE: ACT),
Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), and
Baxter International Inc. (NYSE: BAX). Private wealth members
receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
Biogen Idec Inc. Analyst Notes
On March 31, 2014, Biogen Idec
Inc. (Biogen) announced that the Company plans to release its Q1
2014 results on April 23, 2014,
before the opening of the financial markets. Following the earnings
release, the Company will host a live webcast at 8:00 a.m. ET to discuss the results. According to
Zacks Investment research data, the consensus EPS forecast for Q1
2014 is $2.56.For Q4 2013, the
Company reported total revenues of $2.0
billion, up 38.6% YoY, while the net income came in at
$457.3 million, up 56.5% YoY. The
full analyst notes on Biogen Idec Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/04092014/BIIB/report.pdf
Actavis Plc Analyst Notes
On April 2, 2014, Actavis Plc
(Actavis) announced the opening of its new regional office in
Singapore that will serve as the
Company's headquarters for the Asia
Pacific and Africa (APACA)
region. In addition, the Company informed that its operating
subsidiary Drug Houses of Australia Pte Ltd (DHA) in Singapore will be merged into the Actavis
Brand. Paul Bisaro, Chairman and CEO
of Actavis, commented, "The opening of our new regional
headquarters in Singapore is an
important step in Actavis' global expansion and further evidence of
our commitment to being a leading provider of a full range of
pharmaceutical products in the region." The full analyst notes on
Actavis Plc are available to download free of charge at:
http://www.AnalystsReview.com/04092014/ACT/report.pdf
Bristol-MyersSquibb Co. Analyst Notes
On April 1, 2014, bio
pharmaceuticals firm - Bristol-Myers Squibb Co. (Bristol-Myers)
announced that it plans to release its Q1 2014 results on
April 29, 2014. The earnings release
will be followed by a conference call at 9:00 a.m. EDT in which the Company's executives
will review the results and answer analysts and investors' queries.
According to Zacks Investment research data, the consensus EPS
forecast for Q1 2014 is $0.46.For Q4
2013, the Company reported net earnings of $842 million, or $0.51 per share on a non-GAAP basis, beating
analysts'estimates $0.43 polled by
Thomson Reuters.
The Company had predicted 2014 GAAP EPS in the range of
$1.75 - $1.90 and non-GAAP EPS
between$1.65 - $1.80. The full
analyst notes on Bristol-Myers Squibb Co. are available to download
free of charge at:
http://www.AnalystsReview.com/04092014/BMY/report.pdf
AbbVie Inc. Analyst Notes
On April 4, 2014, AbbVie Inc.'s
(AbbVie) stock declined 2.43% to end the trading session at
$52.20, following the S&P 500
which lost 1.25% over the same day. AbbVie's stock opened the
session at $53.78 and oscillated in
the range of $52.05 - $54.44. A total
of 7.01 million shares were traded, which was above its 30-day
average volume of 5.84 million. Over the past twelve months, the
stock has returned 26.36% outperforming the S&P 500 which
returned 20.07% over the same period. The full analyst notes on
AbbVie Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04092014/ABBV/report.pdf
Baxter International Inc. Analyst Notes
On April 3, 2014, Baxter
International Inc. (Baxter) announced that the Company plans to
hold its quarterly conference call to discuss its Q1 2014 results
on April 17, 2014 at 7:30 a.m. CT. According to Zacks Investment
research data, the consensus EPS forecast for Q1 2014 is
$1.11.The Company in its Q4 2013 and
full year 2013 earnings release had predicted a sales growth of
nearly 13 to 14%, excluding the impact of foreign currency for Q1
2014.In addition, the Company said that it is hopeful of achieving
earnings, before special items, of $1.06 to
$1.09 per diluted share (or GAAP earnings of $1.00 to $1.03 per diluted share including
approximately $0.06 per diluted share
of intangible asset amortization expense) for Q1 2014. The full
analyst notes on Baxter International Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/04092014/BAX/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to
leverage our economy of scale. Most investors do not have time to
track all publicly traded companies, much less perform an in-depth
review and analysis of the complexities contained in each
situation. That's where Analysts Review comes in. We provide a
single unified platform for investors' to hear about what matters.
Situation alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Ananya
Ghosh, a CFA charterholder. However, we are only human and
are prone to make mistakes. If you notice any errors or omissions,
please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Ananya Ghosh, CFA,
has only reviewed the information provided by Analysts Review in
this article or report according to the Procedures outlined by
Analysts Review. Analysts Review is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.AnalystsReview.com
SOURCE Analysts Review